Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab with or without tirzepatide for moderately to severely active Crohn's disease with obesity or overweight
MOH_2025-05-06_014071Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Crohn's disease, obesity and Overweight comparing OMVOH + MOUNJARO with OMVOH + placebo (2 arms). Primary endpoint: Composite remission and weight reduction endpoint. Planned start May 2025; status: not yet recruiting.
02
Drugs
mirikizumabtirzepatide
03
Conditions
Crohn's diseaseobesityOverweight
Beyond the preview
Go deeper on MOH_2025-05-06_014071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-06_014071.